巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Redhill Biopharma Ltd

    RDHL
    0.840
    0.030
    3.43%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Redhill Biopharma Ltd - 延遲價格・最後更新於 01/07 12:14
    最高位
    0.863
    最低位
    0.820
    開市價
    --
    前收市價
    0.870
    成交量(千)
    14.26
    成交額(百萬)
    0.09
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    44.74
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    11.180 - 0.620
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Redhill Biopharma Ltd
    證券代碼
    RDHL.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.
    發行量
    53260079
    公司總部
    21 Ha’arba’a Street
    公司網址
    https://www.redhillbio.com
    公司電郵
    investors@redhillbio.com
    公司電話
    +972 35413131
    暫無內容

    關於

    Redhill Biopharma Ltd(RDHL.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.
    詳細公司背景可參考: https://www.redhillbio.com